Revolution Medicines · 2 hours ago
Senior Director, HEOR/RWE - Lung
Redwood City, California, United States
Full-time
Onsite
Director/Executive
$244K/yr - $305K/yr
10+ years expRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The Senior Director, HEOR/RWE will be responsible for executing HEOR plans related to non-small cell lung cancer, demonstrating the value of products to healthcare organizations, and collaborating with cross-functional teams to deliver evidence supporting product use.
Health CareLife ScienceMedical
Responsibilities
Align with Medical Affairs and Development leadership to design research and deliver evidence consistent with the medical strategy and IEP
Deliver HEOR/RWE tactics with quality and in alignment with agreed upon timing
Provide HEOR/RWE leadership on matrix teams and working groups
Work with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams
Provide HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies
Effectively present research findings to internal and external stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders
Facilitate the communication of the value proposition of Revolution Medicines’ portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions
Engage and collaborate with external partners including payers, health care providers, thought leaders, patient advocates, and decision-makers to establish/maintain strong partnerships and gather insights into research programs
Facilitate and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care
Stay up to date with and add to the advancements in health economics methodologies and best practices
Identify and interface with HEOR & RWE experts and organizations, profile data sources and related organizations as they relate to Revolution Medicines’ portfolio and therapeutic areas
Closely monitor new trends in health policy and payer environment, assess competitive data gaps and communicate to the organization, to help Revolution Medicines build industry-leading capabilities and be on the cutting edge of evidence-based medicine and HEOR research
Qualification
Required
Deep expertise in health economics, outcomes research, patient-reported outcomes or related fields in the biotechnology or pharmaceutical industry
Experience in oncology HEOR and RWE development
Minimum 10 years of relevant experience with an advanced degree in a relevant field (MD, PhD, PharmD)
Track record of high impact publications in HEOR/RWE topics
Strong written and interpersonal communication skills, with an ability to present complex technical information clearly
Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models
Ability to establish relationships with experts in real world evidence (RWE) and therapeutic areas of interest
Preferred
12+ years of relevant experience in the pharmaceutical/biotech industry
Global launch experience
Experience related to NSCLC
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
Pharmaceutical Technology
2026-01-13
Company data provided by crunchbase